Stockscreener 앱 받기
1.895
4.12%
0.075
전일 마감가:
$1.82
열려 있는:
$1.89
하루 거래량:
730.16K
Relative Volume:
0.52
시가총액:
$135.59M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+18.44%
1개월 성능:
-28.76%
6개월 성능:
+51.60%
1년 성능:
+0.00%
1일 변동 폭
$1.81
$1.98
1주일 범위
$1.47
$2.02
52주 변동 폭
$0.5506
$6.19
Citius Oncology Inc Stock (CTOR) Company Profile
명칭
Citius Oncology Inc
전화
(908) 967-6677
주소
11 COMMERCE DRIVE, CRANFORD
CTOR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
1.895 | 129.31M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
153.24 | 67.31B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.66 | 45.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.845 | 43.35B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.52 | 18.68B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
305.40 | 13.44B | 2.99B | 1.21B | 1.13B | 25.06 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-27 | 개시 | Maxim Group | Buy |
Citius Oncology Inc 주식(CTOR)의 최신 뉴스
Citius Oncology Inc. Stock Analysis and ForecastMarket-leading capital gains - Autocar Professional
What drives Citius Oncology Inc. stock priceConsistently exceptional gains - Autocar Professional
Is Citius Oncology Inc. a good long term investmentTriple-digit profit margins - Autocar Professional
What analysts say about Citius Oncology Inc. stockFree Wealth Management Insights - jammulinksnews.com
Citius Oncology Announces Closing of $9.0 Million Public Offering - Eastern Progress
Citius Oncology shares rise 1.31% after-hours after closing a $9.0 million public offering. - AInvest
Should I buy Citius Oncology Inc. stock before earningsShort Term High Return Strategy - Newser
Citius Oncology Completes $9M Public Offering - TipRanks
Citius Oncology launches $15M equity and warrant offering; shares down - MSN
Citius Oncology closes $9 million public offering to support LYMPHIR - Investing.com Australia
Citius Oncology closes $9 million public offering to support LYMPHIR By Investing.com - Investing.com Nigeria
Citius Oncology Raises $9M in Public Offering for LYMPHIR Commercialization - AInvest
Citius Oncology Announces Closing Of $9.0 Million Public Offering - Barchart.com
Citius Oncology Announces Pricing Of $9M "Reasonable Best-Efforts" Public Offering Of 6,818,182 Shares Of Common Stock And Warrants To Purchase Shares Of Common Stock At A Public Offering Price Of $1.32 Per Share - 富途牛牛
Citius Pharmaceuticals shares fall 1.34% after-hours following Citius Oncology's public offering. - AInvest
Citius Oncology’s Chances: Time to Invest? - StocksToTrade
Citius Oncology Announces Pricing of $9.0 Million Public Offering - Finansavisen
Citius Oncology Soars 35.06% on Distribution Deal - AInvest
Citius Oncology Soars 12.34% on Expanded Lymphir Distribution - AInvest
Citius Oncology stock rises after expanding LYMPHIR distribution network - Investing.com
What makes Citius Oncology Inc. stock price move sharplySecure Your Capital Strategy - Newser
Why Citius Oncology Inc. stock attracts strong analyst attentionEarly Breakout Tracker - Newser
Cencora (COR) Partners With Citius Oncology For Immunotherapy Distribution Expansion - simplywall.st
Citius Oncology Shares Climb Following Expansion of LYMPHIR Distribution Network - MSN
Citius Oncology (CTOR): Is LYMPHIR's Launch Priced for Success? - AInvest
Citius Oncology: Is A Lymphir Launch Coming Too Late? - Seeking Alpha
Citius Pharmaceuticals (CTXR) Surges on New Distribution Deal - GuruFocus
Citius Oncology stock rises after expanding LYMPHIR distribution network By Investing.com - Investing.com South Africa
How Citius Oncology Inc. stock performs during market volatilityLow Risk Entry Points - Newser
Citius Oncology Expands Lymphir Distribution With Cencora - MarketScreener
Cencora distribution deal boosts Citius shares - MSN
Citius Oncology expands distribution network for LYMPHIR with Cencora - Investing.com Australia
Citius Oncology expands distribution network for LYMPHIR with Cencora By Investing.com - Investing.com India
Citius stock gains on Cencora distribution deal (CTXR:NASDAQ) - Seeking Alpha
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora - Finansavisen
Citius Oncology Inc (CTOR) 재무 분석
Citius Oncology Inc (CTOR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
3.46%
0.79%
자본화:
|
볼륨(24시간):